COMMUNIQUÉS West-GlobeNewswire

SCYNEXIS Announces Presentations Highlighting the Potent Antifungal Activity of its Second-Generation Fungerp, SCY-247 Against Drug-Resistant Fungi, at the Inaugural Interdisciplinary Meeting on Antimicrobial Resistance and Innovation (IMARI)
28/01/2026
This cross-disciplinary meeting highlights the latest discoveries, technologies and translational strategies driving the next generation of antimicrobial solutions JERSEY CITY, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- [...]
Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinson’s Disease
28/01/2026
• Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology • Nautilus’ development of a single-molecule assay for measuring alpha-synuclein [...]
Bexorg Awarded Grant from The Michael J. Fox Foundation to Identify Translational Biomarkers for TRPML1-Targeted Parkinson’s Disease Therapies
28/01/2026
- TRPML1 is a promising target 1 for Parkinson’s disease treatments and identifying translational biomarkers will help confirm target engagement in clinical studies - Bexorg will leverage its postmortem whole-human [...]
Life Biosciences Announces FDA Clearance of IND Application for ER-100 in Optic Neuropathies
28/01/2026
IND clearance marks the first ever cellular rejuvenation therapy using partial epigenetic reprogramming to reach human clinical trials BOSTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Life Biosciences , Inc., (“Life Bio”) a [...]
Cannara Announces Conditional Approval to List on the Toronto Stock Exchange
28/01/2026
MONTREAL, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (“ Cannara ”, “the Company ”, “ us ” or “ we ”) ( TSXV: LOVE ) ( OTCQX: LOVFF ) ( FRA: 8CB0 ), a vertically integrated producer of premium-grade cannabis [...]
Cannara annonce l'approbation conditionnelle de sa migration vers la Bourse de Toronto
28/01/2026
MONTRÉAL, 28 janv. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la « Société », « nous » ou « notre ») ( TSXV : LOVE ) ( OTCQX : LOVFF ) ( FRA : 8CB0 ), producteur verticalement intégré de cannabis de [...]
Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026
28/01/2026
Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the [...]
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
28/01/2026
Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People [...]
OKYO Pharma Announces Successful Type C Meeting with the FDA
28/01/2026
FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approach LONDON and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage [...]
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
28/01/2026
Images below confirm clinical responses seen in patients with metastatic orbital (eye), temporal (brain), liver, and spine lesions No Bria-IMT™ related discontinuations reported to date Bria-IMT regimen continues under [...]
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
28/01/2026
Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activity Litifilimab has the [...]
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
28/01/2026
BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients [...]
OMass Therapeutics Appoints Jonathan Montagu as Chair of the Board of Directors
28/01/2026
OXFORD, United Kingdom, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins [...]
Seamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss
28/01/2026
-- Collaboration will advance a next generation gene editing approach by combining Seamless’ expertise in developing highly precise and efficient recombinases with Lilly’s extensive development expertise in genetic [...]
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
28/01/2026
Teva delivers 3 consecutive years of growth - 2025 revenues of $17.3 billion, an increase of 4% year-over-year (YoY) in U.S. dollars, or 3% in local currency (LC) terms, compared to 2024. Excluding Japan BV, revenues [...]
Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
28/01/2026
Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases Interim data from additional [...]
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
28/01/2026
RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, [...]
Vireo Growth Inc. Enters into Non-Binding Memorandum of Understanding to Acquire The Hawthorne Gardening Company from ScottsMiracle-Gro
28/01/2026
Planned share-based transaction is expected to be completed during the first fiscal quarter of 2026 Vireo plans to appoint Chris Hagedorn to its Board of Directors MINNEAPOLIS, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vireo [...]
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
28/01/2026
SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and [...]

Pages